News >

DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma

Jason Harris
Published: Thursday, Feb 15, 2018

Dr. Frederick F. Lang

Frederick F. Lang, MD
Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment, according to phase I data published in the Journal of Clinical Oncology.

“In all, these results provide the first clinical correlates that DNX-2401 can induce a direct oncolytic effect followed by an antitumor immune response,” the investigators wrote. “Insofar as DNX-2401 is highly efficient because of expanded infectivity conferred by the RGD motif, and insofar as it is capable of enhancing antigen presentation, we speculate that these effects lead to immune cell infiltration and antitumor activity.”
Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma [published online February 12, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.8219.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication